1. Home
  2. QH vs ADTX Comparison

QH vs ADTX Comparison

Compare QH & ADTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

QH

Quhuo Limited American Depository Shares

HOLD

Current Price

$1.05

Market Cap

1.1M

ML Signal

HOLD

Logo Aditxt Inc.

ADTX

Aditxt Inc.

HOLD

Current Price

$0.51

Market Cap

1.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
QH
ADTX
Founded
2012
2017
Country
China
United States
Employees
N/A
N/A
Industry
Business Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.1M
1.1M
IPO Year
2019
2020

Fundamental Metrics

Financial Performance
Metric
QH
ADTX
Price
$1.05
$0.51
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
157.4K
161.6K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$133,985.00
Revenue This Year
N/A
$15,768.94
Revenue Next Year
N/A
N/A
P/E Ratio
$2.86
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.06
$0.02
52 Week High
$10.85
$12.92

Technical Indicators

Market Signals
Indicator
QH
ADTX
Relative Strength Index (RSI) 57.69 33.81
Support Level $1.06 $0.05
Resistance Level $1.08 $1.10
Average True Range (ATR) 0.10 0.07
MACD 0.03 0.01
Stochastic Oscillator 93.58 7.70

Price Performance

Historical Comparison
QH
ADTX

About QH Quhuo Limited American Depository Shares

Quhuo Ltd is a gig economy platform focusing on local life services in China. It provide tech-enabled, end-to-end operational solutions to consumer service businesses, including on-demand delivery solutions, mobility service solutions, housekeeping and accommodation solutions, and other services. Its three operating segments, include (i) on-demand delivery solutions, (ii) mobility service solutions, and (iii) housekeeping and accommodation solutions and other services.

About ADTX Aditxt Inc.

Aditxt Inc is a life sciences company that develops, builds, and grows innovations with a focus on monitoring and modulating the immune system. It develops products designed to induce tolerance to transplanted organs. Its portfolio consists of two programs Adimune and AditxtScore. It firm's immunosuppressive (anti-rejection) drugs have made possible life-saving organ transplantation procedures and blocking of unwanted immune responses in autoimmune diseases. It is also developing a technology called Apoptotic DNA Immunotherapy (ADi) ADI-100, which utilizes a novel approach that mimics, the way bodies naturally induce tolerance to tissues.

Share on Social Networks: